Antidrug antibodies to adalimumab do not associate with immunologically related adverse events
IntroductionUnwanted immune responses (UIRs) to biologics can negatively impact treatment efficacy and pharmacokinetics and/or induce adverse events (AEs). We characterized the UIR profile of adalimumab (ADL) using data from a phase 3, randomized, inte…